Cascadian Therapeutics amends HER2CLIMB phase 2 trial of tucatinib
Cascadian Therapeutics announced that following a meeting with the FDA and external Steering Committee, it has amended the HER2CLIMB Phase 2 clinical trial of tucatinib by increasing the sample size so that, if successful, the trial could serve as a single pivotal study to support registration. December 07, 2016